Preliminary results from eight patients in the phase I portion of the Acclaim-1 clinical study evaluating Reqorsa immunogene therapy (quaratusugene ozeplasmid) with Tagrisso (osimertinib) in patients with advanced, EGFR mutant non-small cell lung cancer whose disease progressed after Tagrisso showed that Reqorsa was generally well tolerated, as there were no dose limiting toxicities. Promising efficacy results were also observed.
Weizhou Zhang, who is leading research on cancer immunotherapeutics and basic mechanisms of cancer immunology, was named co-leader of the UF Health Cancer Institute’s Immuno-Oncology and Microenvironment research program.
